NetraMark Holdings (TSE:AIAI) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
NetraMark Holdings Inc., a leader in AI software for clinical trial analytics, has reported significant progress in Q3, including the full commercialization of its proprietary AI platform validated by a major pharmaceutical company. They’ve refined their market strategy to focus on CNS and Oncology sectors and have secured a substantial client with over $10B USD market cap, resulting in four contracts. NetraMark’s AI technology aims to mitigate the high failure rates of clinical trials in the pharmaceutical industry by improving decision-making and potentially saving millions in investment.
For further insights into TSE:AIAI stock, check out TipRanks’ Stock Analysis page.
